Falls Prevention and Sarcopenia

European consensus reframed sarcopenia in 2019 in a way that matters clinically: low muscle strength, not low muscle mass, became the primary characteristic. Strength predicts outcome better than mass does, and it is far easier to measure, so the diagnosis now begins with function.

The pathway has four stages. Case finding uses a short screening questionnaire covering strength, walking, rising from a chair, stair climbing and falls, or simply clinical suspicion where the picture is obvious. Assessment then measures strength, using either handgrip dynamometry, where the thresholds are below 27 kg for men and below 16 kg for women, or a chair stand test, where taking longer than 15 seconds for five rises is the threshold. Low strength alone establishes probable sarcopenia, and that is enough to act on. Confirmation requires demonstrating low muscle quantity or quality, for which dual-energy X-ray absorptiometry (DXA) is one practical clinical option, with bioelectrical impedance, computed tomography or magnetic resonance techniques used depending on context and availability. Severity is then graded by physical performance, most commonly gait speed, with 0.8 m/s or slower indicating severe disease.

Two practical points follow. Grip strength and the chair stand test do not identify the same people, so the choice of test changes who gets diagnosed, and the chair stand is a composite functional test rather than a pure measure of muscle strength. And probable sarcopenia is an actionable diagnosis in its own right: waiting for imaging confirmation before starting resistance training would be a mistake.

Falls are multifactorial, and exercise addresses only some of the factors, which is why single-intervention approaches disappoint. The intrinsic contributors include reduced muscle strength and, in particular, reduced muscle power, impaired balance and postural control, gait changes, visual impairment, cognitive impairment, postural hypotension, peripheral neuropathy, foot problems and continence urgency prompting rushed movement. Medication review is a core component, particularly where psychotropic, sedating or anticholinergic medicines are involved. Blood pressure lowering medicines matter too, though the issue is postural hypotension, excessive lowering, timing and individual response rather than antihypertensives as a class. Extrinsic contributors include lighting, floor surfaces, loose rugs, footwear and the absence of rails.

Power matters more than raw strength for falls specifically, and this is a point worth understanding rather than memorising. Recovering from a trip requires generating force quickly, within a few hundred milliseconds, to reposition a limb before balance is lost. Power is the product of force and velocity, and it declines earlier and faster with age than maximal strength does, largely because type II fibres are lost preferentially. That is why high-velocity resistance work has moved up the agenda, although the evidence for power training is stronger for improving power and function than for directly reducing falls. A related consequence is fear of falling, which is itself a risk factor: the person who restricts activity to avoid falling deconditions further and becomes more likely to fall, and breaking that cycle is part of the treatment.

The evidence base here is unusually good, and the details of the prescription are what determine whether it works.

The established core is progressively challenging balance exercise together with functional exercise, usually combined with progressive resistance training. Programmes that reduce the base of support, shift the centre of mass or reduce reliance on the arms produce results. Walking alone may not provide sufficient progressive balance challenge and should not replace a targeted programme. High-velocity power work may be added where it is safe and appropriate, but it is not a mandatory component of every programme. Structured home-based programmes such as the Otago approach, and group programmes of the same design, are the models that carry the evidence.

Dose is where most programmes fall short. Effective programmes generally require multiple weekly sessions sustained over months with progression and ongoing maintenance, and greater falls reduction is associated with programmes that genuinely challenge balance and provide a substantial weekly volume, commonly cited as more than around three hours a week. Older sources quote a fixed total of roughly 50 hours, but current UK guidance emphasises progressive individualised exercise rather than a single universal hour threshold. Benefits decline when training is not maintained. UK guidance frames the same territory as strength, balance and flexibility activity on at least two days a week for older adults, noting that these can be built into sessions that also include aerobic activity rather than always being additional. For the frailest, the starting point is different again: short bouts of five to ten minutes of low intensity activity, prioritising balance and strength, progressing duration before intensity. Prescription should account for supervision, safe transfers, postural symptoms, bone loading and spinal precautions, cognition and previous falls, particularly where there is significant frailty, dementia or a history of vertebral fracture.

In practice the assessment and the intervention run together. A patient presenting after a fall, or with a positive screening questionnaire, needs a multifactorial assessment. Current UK guidance covers lying and standing blood pressure, cognition, continence, vision, hearing, feet and footwear, medication review, gait and balance, osteoporosis risk and home hazards, alongside a strength measure and a performance measure. Bone health belongs in the same conversation, because the fall and the fracture are separate problems with separate treatments, and identifying one without addressing the other leaves the job half done.

Protein intake is worth raising alongside the exercise, since resistance training and adequate protein together preserve muscle more effectively than either alone. Advice should be individualised for total intake, appetite, renal disease, dietary pattern and malnutrition risk, with dietetic input rather than a generic instruction to eat more protein. The newer consideration is glucagon-like peptide-1 agonist weight management drugs, on which both fat and muscle are lost; UK guidance now singles out strengthening activity as particularly important for anyone taking or recently taking these agents. Finally, set expectations honestly. Strength gains in the first weeks are largely neural and will not be visible, the programme needs months rather than weeks, and benefits decline when training is not maintained. Framing it as ongoing maintenance rather than a course of treatment gives it a much better chance of lasting.

• •Low muscle strength, not low mass, is now the primary characteristic of sarcopenia.
• •Grip strength thresholds are below 27 kg for men and below 16 kg for women; a chair stand over 15 seconds for five rises is the alternative.
• •Low strength alone establishes probable sarcopenia, which is actionable without waiting for imaging.
• •Gait speed of 0.8 m/s or slower grades severity rather than making the diagnosis.
• •Progressively challenging balance exercise is the core component; walking alone rarely provides sufficient challenge.
• •Effective programmes need multiple weekly sessions sustained over months, with progression and ongoing maintenance.